Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Stavudine
Drug ID BADD_D02068
Description A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Indications and Usage For the treatment of human immunovirus (HIV) infections.
Marketing Status approved; investigational
ATC Code J05AF04
DrugBank ID DB00649
KEGG ID D00445
MeSH ID D018119
PubChem ID 18283
TTD Drug ID D0Z8EX
NDC Product Code 65015-672; 65862-342; 68554-0015; 65862-263; 53104-0111; 65015-795; 68554-0045
UNII BO9LE4QFZF
Synonyms Stavudine | D4T | 2',3'-Didehydro-3'-deoxythymidine | 2',3' Didehydro 3' deoxythymidine | 2',3'-Didehydro-2',3'-dideoxythmidine | Zerit | BMY-27857 | BMY 27857 | BMY27857 | Stavudine, Monosodium Salt
Chemical Information
Molecular Formula C10H12N2O4
CAS Registry Number 3056-17-5
SMILES CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinitis11.01.13.004; 22.07.03.006--
Sensory loss17.02.07.007---
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.003--
Stillbirth08.04.01.006; 18.01.02.002---
Stomatitis07.05.06.005--
Thinking abnormal17.02.05.023; 19.10.03.001---
Thrombocytopenia01.08.01.002---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.0030.000282%
Weight decreased13.15.01.005--
Fat redistribution14.08.04.002---
Lipodystrophy acquired14.08.04.008; 23.07.01.0030.002117%-
Lymphatic disorder01.09.01.003---
Foetor hepaticus07.01.06.026; 09.01.05.006---
Musculoskeletal discomfort15.03.04.001---
Mitochondrial toxicity12.03.01.009; 14.11.02.0010.001976%-
Affect lability19.04.01.001---
Body fat disorder14.08.04.012---
Metabolic disorder14.11.01.001---
Neurological symptom17.02.05.010---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Inflammation08.01.05.007; 10.02.01.089---
Malnutrition14.03.02.004---
Mental disorder19.07.01.002---
Decreased appetite08.01.09.028; 14.03.01.005--
Blood disorder01.05.01.004---
Autoimmune disorder10.04.04.003--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene